Q4 EPS Estimates for GeoVax Labs Raised by Noble Financial

GeoVax Labs, Inc. (NASDAQ:GOVX) – Equities researchers at Noble Financial raised their Q4 2024 earnings per share (EPS) estimates for GeoVax Labs in a research note issued to investors on Wednesday, November 20th. Noble Financial analyst R. Leboyer now forecasts that the company will earn ($1.00) per share for the quarter, up from their previous forecast of ($1.74). Noble Financial has a “Outperform” rating and a $10.00 price target on the stock. The consensus estimate for GeoVax Labs’ current full-year earnings is ($4.49) per share. Noble Financial also issued estimates for GeoVax Labs’ Q1 2025 earnings at ($0.43) EPS, Q2 2025 earnings at ($0.50) EPS, Q3 2025 earnings at ($0.61) EPS, Q4 2025 earnings at ($0.68) EPS and FY2025 earnings at ($2.22) EPS.

Several other equities analysts also recently issued reports on GOVX. HC Wainwright restated a “buy” rating and issued a $8.00 price objective on shares of GeoVax Labs in a research note on Friday, November 15th. Alliance Global Partners started coverage on shares of GeoVax Labs in a research note on Monday, November 11th. They issued a “buy” rating and a $15.00 price objective for the company. Four analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, GeoVax Labs currently has a consensus rating of “Buy” and a consensus price target of $13.25.

GeoVax Labs Price Performance

NASDAQ:GOVX opened at $2.70 on Friday. The business’s fifty day moving average price is $2.33 and its 200 day moving average price is $2.64. GeoVax Labs has a 12 month low of $1.09 and a 12 month high of $11.18.

GeoVax Labs (NASDAQ:GOVX) last posted its earnings results on Tuesday, November 12th. The company reported ($0.91) EPS for the quarter, beating the consensus estimate of ($1.29) by $0.38. The business had revenue of $2.79 million during the quarter, compared to analysts’ expectations of $1.84 million. During the same period last year, the company earned ($4.80) EPS.

Institutional Investors Weigh In On GeoVax Labs

An institutional investor recently bought a new position in GeoVax Labs stock. Virtu Financial LLC bought a new position in shares of GeoVax Labs, Inc. (NASDAQ:GOVX) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 40,210 shares of the company’s stock, valued at approximately $97,000. Virtu Financial LLC owned 0.43% of GeoVax Labs as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 6.09% of the company’s stock.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.